Showing 1216 Results
Last Chance to Apply: Post-Doctoral Fellowship in the Policy Impact of CER
Are you a post-doctoral student interested in comparative effectiveness research? If so, you should consider applying for the new post-doctoral Fellowship in the Policy Impact of Comparative…
NPC Examines CER as Health Reform Takes Hold
What's on the National Pharmaceutical Council's (NPC) radar for 2013? NPC President Dan Leonard takes a closer look at comparative effectiveness research (CER), state health exchanges and benefits,…
Quantifying the Impact of CER: Let Us Avoid the Mistakes of the Past
In his latest "From Methods to Policy" column, published in the January 2013 issue of the Journal of Comparative Effectiveness Research, NPC Chief Science Officer Dr. Robert Dubois traces the history…
National Pharmaceutical Council 2012 Annual Report
The 2012 Annual Report highlights NPC's research, educational and partnership activities throughout the year.
US v. Caronia: Related Resources
The 2nd U.S. Circuit Court of Appeals' recent decision on United States vs. Caronia raises a big question for the pharmaceutical industry: will the decision have broader applicability to comparative…
US v. Caronia and CER Communications
A landmark appeals court ruling could open the door for the pharmaceutical industry to discuss information about comparative effectiveness research (CER) results, even when the data examines off…
PCORI Hosts Two Workshops to Generate, Prioritize Specific Research Topics
The Patient-Centered Outcomes Research Institute (PCORI) is hosting two workshops this week to solicit input from patients, researchers and other health care stakeholders on the topics the agency…
The Myth of Average: Why Individual Patient Differences Matter
How can comparative effectiveness research (CER) be conducted so that we understand which patients are likely to respond to what therapies? How can CER be implemented in such a way as to balance…
Why Is It Important for Researchers to Consider Individual Treatment Effects?
Why is it important for researchers to consider individual treatment effects, or heterogeneity? Dr. David Meltzer, director of the Center for Health & the Social Sciences at the University of…
Understanding Individual Treatment Effects
Next week, health care stakeholders will convene in Washington, DC, to explore the role and challenges of individual treatment effects, or heterogeneity, in developing treatment recommendations,…
Why Individual Patient Differences Matter
At the end of this month, a diverse group of health care stakeholders will convene at a public meeting in Washington, DC, to discuss one of the unintended consequences of comparative effectiveness…
Current Challenges in Comparative Effectiveness Research
The National Pharmaceutical Council sponsored a cluster of articles in the October 2012 issue of Health Affairs, "Current Challenges in Comparative Effectiveness Research," and a related briefing on…
Interested in Comparative Effectiveness Policy? Apply for Our Post-Doctoral Fellowship
In recent years, public and private funding for comparative effectiveness research (CER) has dramatically increased, with the intention of providing useful information to help patients and providers…
Partnerships in Real-World Evidence Explored at PCMA Annual Meeting
Why are partnerships on real-world evidence among payers and pharmaceutical companies becoming more prevalent? That’s what National Pharmaceutical Council President Dan Leonard asked participants…